iBio ($IBIO) Stock Hub 2026: IBIO-600 Cleared Single-Dose Phase 1, $88 Million In Cash Funds Into 2028

01Executive Summary

iBio is no longer a purely preclinical antibody-discovery story. It dosed the first Phase 1 participant in IBIO-600, a long-acting antibody intended to neutralise myostatin and GDF11, on June 2, 2026, and by its fiscal 2026 close (June 30) had dosed 31 of the 32 participants planned for the single ascending dose portion across all four cohorts, with no safety findings that precluded escalation. The company is now preparing to advance IBIO-600 into the multiple ascending dose portion of the same trial, keeping a 2027 window for the fuller human safety, pharmacokinetic and pharmacodynamic dataset.

The transition matters, but it does not close the central evidence gap. The published IBIO-600 package is still built from laboratory assays, mouse work and a pharmacokinetic study in three aged obese cynomolgus monkeys without a concurrent control group. The peer-reviewed paper reports a 52.4-day half-life in those monkeys, but the mouse lean-mass preservation signal in combination with semaglutide was modest and not statistically significant. No human efficacy or body-composition result exists yet.

The second asset, IBIO-610, may become equally important. iBio reported that one dose of an Activin E antibody reduced active Activin E by 98% at week four and 97% at week eight in non-human primates, and that combining it with semaglutide reduced lean-mass loss by 73% versus semaglutide alone. Those are company-sponsored preclinical disclosures. The full dataset is scheduled for EASD on October 1, 2026 and has not yet been peer reviewed or tested in humans.

The balance sheet is adequate for the next clinical step but not simple. At the fiscal 2026 year-end (June 30, 2026) the company held $56.4 million of cash and equivalents and $31.6 million of investments in debt securities, a combined $88.0 million, up from $8.6 million of cash and no debt-security investments a year earlier. Full fiscal-year operating cash use was $23.2 million, up from $15.3 million in fiscal 2025. The FY2026 10-K states this position funds operations into the fourth quarter of fiscal 2028, but Phase 1 expansion and a second clinical program entering the clinic can make the historical burn rate a poor guide to the next two years.

The share count is the bigger analytical trap. The preliminary proxy filed August 20 reports 60.85 million common shares and 93.38 million pre-funded warrants. Because a pre-funded warrant carries only a nominal remaining exercise price, it is economically closer to an outstanding share than to an ordinary option. At $1.26 — the close of September 2, 2026 — the common-only value is about $76.7 million; common plus pre-funded warrants implies about $194.3 million. Neither number should be presented without stating the convention and the pricing date.

02What The Company Actually Is Today

iBio describes itself as an AI-enabled biotechnology company developing precision antibodies. The operating model combines target selection, epitope steering, mammalian display and human antibody libraries. Those tools are intended to find binders against difficult targets and optimise their specificity, half-life and manufacturability.

For investors, the platform is not yet a stand-alone business with validated recurring economics. The value sits in the assets it produces: one program in Phase 1, two named cardiometabolic programs in preclinical development, an amylin antibody in optimisation, an undisclosed discovery target and legacy oncology assets available for partnering.

The company pipeline page still labels IBIO-600 as “IND-Enabling,” while the trial registry and the June 2 dosing announcement show that Phase 1 has begun. For stage and timing, this Hub uses the dated trial and filing evidence rather than the stale website label.

iBio also rebuilt its clinical leadership around the same period. It added Elizabeth Stoner, M.D. to the Board, and appointed Molly Carr, M.D. — a 30-year endocrinology and metabolic-disease veteran most recently from Eli Lilly — as Chief Medical Officer effective July 31, 2026, with a base salary of $470,000 and an inducement stock option covering 430,000 shares, announced August 4, 2026.

03IBIO-600: What The Phase 1 Trial Can And Cannot Prove

NCT07487376 is a first-in-human, randomised, placebo-controlled, single-dose study in adults with overweight or obesity. The registry estimates 32 participants across five arms, age 18 to 65, body-mass index 27.0 to 34.9, at sites in Australia.

The August 28, 2026 fiscal-year results release reports that the single ascending dose (SAD) portion is complete: 31 of the 32 planned participants dosed across all four planned cohorts, with no safety findings identified that precluded dose escalation. iBio says it is now preparing to advance IBIO-600 into the multiple ascending dose (MAD) portion of the same trial. That is company-reported safety framing, not an independent adjudication, and it does not by itself establish a pharmacodynamic or efficacy signal.

The primary objective is safety and tolerability through day 252. Secondary measures cover pharmacokinetics and pharmacodynamics through approximately 36 weeks. That long observation window fits the intended long half-life, but it also means that the first useful dataset is measured in months rather than weeks.

The registry describes quadruple masking, while the company’s June 2 release calls the study double-blind. This is a documentation mismatch, not evidence of a design failure, but it should be reconciled when a protocol or updated registry record becomes available.

The registry lists estimated primary completion in May 2027; the company release says study completion is expected in the second half of 2027. The defensible catalyst window is therefore 2027, while the exact month should remain provisional.

04The Published IBIO-600 Evidence — And Its Limits

The primary scientific paper was published in Scientific Reports in June 2026, DOI 10.1038/s41598-026-59882-0, PubMed PMID 42380199. It reports in-vitro characterisation, mouse experiments and pharmacokinetics in aged obese cynomolgus monkeys.

The strongest translational observation is pharmacokinetic: an estimated 52.4-day half-life in non-human primates. If that property carries into humans, it could support infrequent dosing. The antibody also neutralised myostatin and GDF11 in laboratory assays, consistent with the intended mechanism.

The efficacy-like evidence is materially weaker. In mice receiving semaglutide, the combination with IBIO-600 produced a modest lean-mass preservation signal that the authors describe as not statistically significant. Body weight, food intake and fat-mass differences were not significant. In the monkey experiment there were only three animals, no concurrent control group and insufficient power for body-composition inference; the study’s practical purpose was pharmacokinetics.

The paper was funded by iBio and most authors were employees of iBio or AstralBio. That does not invalidate the work, but it heightens the need for independent replication and for human data. The short mouse duration and absence of functional outcomes such as strength or performance also limit what “lean mass preservation” can mean clinically.

05IBIO-610: The Activin E Bet

IBIO-610 is an antibody against Activin E, a liver-derived member of the TGF-β family associated with adiposity and energy metabolism. iBio is developing it as a potential obesity and cardiometabolic therapy, including combination use with GLP-1 drugs.

In a July 1 SEC-filed release, the company said one dose reduced active Activin E by 98% at week four and 97% at week eight in non-human primates. In the same disclosed study, combining the antibody with semaglutide reduced lean-mass loss by 73% versus semaglutide alone and produced greater visceral- and total-fat reduction.

The release does not provide the full sample size, dispersion, prespecified analysis or statistical power. Those omissions prevent an independent judgement of robustness. The scheduled EASD presentation on October 1, 2026, number 759, is therefore a genuine de-risking event only if the full dataset supplies denominators, variability and a coherent dose-response.

Management guides the first human study for the first half of 2027. Until an IND is cleared and the first participant is dosed, that remains company guidance rather than a completed catalyst.

06IBIO-800, Amylin And The Rest Of The Pipeline

IBIO-800 is a bispecific antibody intended to inhibit myostatin, GDF11 and Activin A. The company positions it for pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, and for obesity-related muscle preservation. The concept is broader pathway coverage than IBIO-600, but that also raises the burden of demonstrating selectivity and tolerability.

In March the company guided selection of an optimised development candidate in the third quarter of calendar 2026. The August 28, 2026 fiscal-year results confirm that milestone: iBio has selected a development candidate and advanced IBIO-800 into IND-enabling development, including CMC and IND-enabling nonclinical work, with an initial focus on PH-HFpEF. The company has not disclosed the candidate’s composition-of-matter details or a specific IND-filing date.

The amylin program grew materially in fiscal 2026: iBio in-licensed all rights to AstralBio’s amylin receptor antibody program, described as a portfolio of next-generation antibody agonists that includes AMY1- and AMY3-selective agonists, dual AMY1/AMY3 agonists and dual amylin-and-calcitonin receptor agonists, all still in preclinical characterisation. “Target 4” remains earlier and undisclosed. None of these should receive material valuation before candidate selection and comparative data. Legacy oncology assets are a different story: the FY2026 10-K discloses that iBio completed a strategic pivot away from immune-oncology during the year, fully impairing its IBIO-101 (RTX-003) indefinite-lived intangible asset for $5.0 million and ceasing active marketing of its oncology programs. Those assets are no longer being actively shopped for partners.

The pipeline is therefore concentrated, by design as well as by history. IBIO-600 carries the only human readout path, IBIO-610 carries the nearest large preclinical catalyst, and the wind-down of oncology means there is no longer a second therapeutic area to offset a failure in the lead mechanism.

07The Latest Financials In Order

iBio filed its FY2026 Form 10-K on August 28, 2026, for the fiscal year ended June 30, 2026. Audited full-year revenue was $0.1 million, confirming that this remains a development-stage business rather than a commercial one.

At June 30, 2026 total assets were $99.1 million and total liabilities $13.4 million, of which $11.7 million was current. Stockholders’ equity was $85.7 million, up from $14.9 million a year earlier. Loss per share was $(0.32) on a weighted-average share count of 104.06 million, against $(1.75) on 10.50 million shares in fiscal 2025; the improvement in the per-share figure reflects the far larger share count from the August 2025 public offering, the January 2026 private placement and warrant exercises during the year, not a smaller underlying loss.

08Cash Runway: Adequate, But Management-Dependent

The balance sheet held $56.395 million of cash and cash equivalents and $31.644 million of investments in debt securities at June 30, 2026, a combined $88.039 million, plus $228,000 of restricted cash. That compares with $8.582 million of cash and no debt-security investments a year earlier — the balance sheet was transformed by the August 2025 public offering, the January 2026 private placement and warrant exercises during the year.

The FY2026 Form 10-K states that this position is anticipated to be sufficient to support operations into the fourth quarter of fiscal year 2028. That is a useful planning guide, not an audited runway forecast. It depends on trial size, manufacturing commitments, hiring and whether IBIO-610 enters the clinic on schedule.

Full fiscal-year 2026 operating cash use was $23.2 million, up from $15.3 million in fiscal 2025. Applying that mechanically to available liquidity would still overstate precision, because fiscal 2026 does not yet contain a mature multiple-ascending-dose Phase 1 program or two simultaneous clinical-stage assets in the clinic.

iBio also has a February 2026 at-the-market facility with Jefferies for up to $100 million. No shares had been sold under it as of June 30, 2026. The ATM is optional financing capacity; it is also a real overhang if the share price strengthens before clinical proof arrives.

09The Capital Structure: Why The Headline Market Cap Misleads

The preliminary proxy filed August 20 reports 60,853,561 common shares outstanding and 93,382,863 pre-funded warrants. It also reports 129,233,048 shares issuable under all outstanding warrants, 3,248,513 shares underlying options and 250,761 shares reserved under the equity plan.

Pre-funded warrants have only a nominal exercise price and are included with common shares in the loss-per-share denominator. The FY2026 weighted-average denominator was 104.06 million shares, which under GAAP folds in pre-funded warrant equivalents alongside common shares outstanding; the prior fiscal year’s denominator was just 10.50 million. That accounting treatment is the clearest reason not to value iBio on common shares alone.

The last line is deliberately not multiplied into a “fully diluted market cap.” Ordinary warrants carry exercise prices and can bring cash into the company, while some may expire out of the money. Treating every instrument as identical would be as misleading as ignoring them.

The annual-meeting proposal would raise authorised common shares from 275 million to 500 million. The preliminary proxy says only 81.4 million authorised but unissued shares were available before the proposal. Approval would not itself issue stock, but it would expand the board’s future financing capacity materially.

The same preliminary filing lists several 5% holders, many at 9.99% positions consistent with ownership blockers, including Frazier, Sirenia, Affinity, Cormorant, Adage and SilverArc; Vestal Point is listed at 6.46%. Directors and executive officers as a group are listed at 1.64%. Because this is a preliminary proxy with bracketed record-date text, those percentages should be treated as a filing snapshot rather than a final meeting ownership table.

10Catalyst Calendar

No PDUFA date, FDA approval decision or pivotal clinical readout exists in the current calendar. Any source presenting one is confusing an early clinical obesity pipeline with a late-stage drug program.

11Platform, Intellectual Property And Manufacturing

iBio’s discovery stack includes epitope steering, mammalian display and fully human antibody libraries. The company argues that the combination can identify antibodies against difficult epitopes while keeping development properties suitable for manufacturing. These are company claims until repeat programs demonstrate faster or more productive discovery than conventional workflows.

The economic moat will not be the phrase “AI-enabled.” It will be molecule-specific composition-of-matter claims, method-of-use coverage, manufacturing know-how and clinical differentiation. The SEC filings describe licensed and internally developed rights, but a useful patent-life model requires issued-claim review by asset and jurisdiction rather than a single corporate expiry date.

iBio no longer operates as the former plant-based contract-development story that older market summaries may imply. The current pipeline is antibody based, and the critical manufacturing question is whether long half-life and multi-target designs can be produced at acceptable yield and quality as doses scale.

12Analysts, Ownership And Market Data

The company’s analyst-coverage page lists B. Riley Securities, Brookline Capital Markets, Chardan, Jones Research, Leerink Partners, LifeSci Capital, Lucid Capital Markets, Oppenheimer, Raymond James and others. The page identifies covering firms but does not publish target prices or a consensus valuation.

That distinction matters. A target copied from an aggregator can be stale, can use a different share-count convention and can predate the warrant exercises. This Hub does not manufacture an analyst “consensus” from second-hand pages.

The reference price is $1.26, the close of September 2, 2026. At that price, trading below $2 does not by itself make the company inexpensive: the 154.24 million common-plus-pre-funded economic base implies about $194.3 million before considering other warrants, options, cash and liabilities.

Retail discussion can be useful for measuring attention around EASD or the first human data, but it cannot validate a biological mechanism. The live $IBIO Stocktwits stream is therefore linked as a sentiment feed, not cited as evidence. The block below is a snapshot of that flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

13The Valuation Problem: Too Early For A Defensible Target

A conventional discounted-cash-flow model is not meaningful: iBio has no product revenue, no clinical efficacy data, no validated dose and no probability-adjusted launch timeline. A risk-adjusted net-present-value model would be dominated by assumptions rather than evidence.

The correct starting point is the economic share base. On common plus pre-funded warrants, the equity value is roughly $194 million at $1.26 (the close of September 2, 2026). Cash and investments at the fiscal 2026 year-end totalled $88.0 million. Subtracting that mechanically would still not produce a clean enterprise value, because the cash date, the security price date and ongoing spend do not align.

What appears priced in is an inference, not a fact: the market gives meaningful value to the platform and to successful early translation, but not the valuation of a clinically validated obesity franchise. Human safety or pharmacodynamic failure would remove much of that optionality; a clean long-half-life and target-engagement result would move the debate from “does it translate?” to “how large and expensive must the efficacy study be?”

14What Bulls See

The single ascending dose portion is done. iBio dosed 31 of the 32 planned IBIO-600 participants with no safety findings that blocked escalation, moving the trial toward the multiple ascending dose portion and a defined 2027 evidence window.

The balance sheet was rebuilt in fiscal 2026. Cash and investments grew from $8.6 million to $88.0 million, funded by the August 2025 public offering, the January 2026 private placement and warrant exercises, without yet drawing on the $100 million Jefferies ATM.

A potentially useful dosing profile. A 52.4-day half-life in non-human primates, if it translates, could support infrequent dosing and combination use.

Two distinct body-composition mechanisms. IBIO-600 targets myostatin/GDF11 while IBIO-610 targets Activin E, giving the company more than one path to muscle and fat outcomes.

A near-term full-data event. EASD on October 1 can replace a press-release headline with an inspectable IBIO-610 dataset.

Liquidity through the first human proof window. Management’s fiscal Q4 2028 runway guidance extends beyond the expected IBIO-600 Phase 1 completion window.

Specialist institutional participation. The preliminary proxy lists several biotechnology funds near 10% ownership positions, suggesting informed capital remains engaged.

Platform upside is not required for the first inflection. One clean IBIO-600 human pharmacology dataset can validate the discovery stack more credibly than additional preclinical programs.

15What Bears See

Still no human efficacy. IBIO-600 has cleared single-ascending-dose safety, but the trial is not powered to establish durable body-composition benefit, and the multiple-ascending-dose portion has not yet started.

The net loss nearly doubled. Fiscal 2026 net loss was $33.0 million, up from $18.4 million, including a $5.0 million impairment as the company wound down its oncology programs.

The strongest animal efficacy claims are fragile. The monkey IBIO-600 experiment used three animals without a concurrent control; the mouse lean-mass signal with semaglutide was not statistically significant.

IBIO-610 is still a press-release dataset. The disclosed release omits the full sample size and statistical detail. EASD can improve or weaken the story.

The share count is much larger than the headline. Pre-funded warrants lift the economic base from 60.85 million common shares to 154.24 million share equivalents before other warrants and options.

Financing capacity is explicit. A $100 million ATM exists, and shareholders are being asked to raise authorised shares from 275 million to 500 million.

Clinical spending has already risen sharply and will keep rising. R&D expense grew from $8.3 million to $19.6 million in fiscal 2026, before IBIO-610’s planned clinical entry or a mature multiple-ascending-dose IBIO-600 program.

Management ownership is limited. Directors and officers as a group are listed at 1.64% in the preliminary proxy, below the specialist-fund positions.

16Scenario Framework

These scenarios organise evidence and financing paths. They are not forecasts, ratings or price targets.

The middle path is more likely than either extreme: acceptable Phase 1 safety and exposure, an intriguing but not definitive pharmacodynamic signal, and a financing decision before any controlled efficacy study can read out.

17Bottom Line

iBio has earned a place on a biotechnology watchlist because it has moved from a discovery story to a first-in-human program that has cleared its first safety hurdle. The lead asset has a plausible mechanism, a long non-human-primate half-life, and has now dosed nearly all of its single-ascending-dose cohorts without a safety finding that blocked escalation.

What is verified: IBIO-600’s first participant was dosed June 2, 2026, and by fiscal year-end 31 of the 32 planned single-ascending-dose participants had been dosed with no safety findings precluding escalation; NCT07487376 is recruiting an estimated 32 adults in a single-dose Phase 1 study; the scientific paper reports a 52.4-day non-human-primate half-life; the mouse combination lean-mass result was not statistically significant; the monkey experiment had three animals and no concurrent control; audited fiscal 2026 cash and investments in debt securities were $88.0 million at June 30, 2026, up from $8.6 million a year earlier; fiscal 2026 net loss was $33.0 million on operating cash use of $23.2 million; iBio selected an IBIO-800 development candidate and advanced it into IND-enabling development; the company fully impaired its IBIO-101 oncology asset for $5.0 million and ceased marketing its oncology programs; and the preliminary proxy reports 60.85 million common shares plus 93.38 million pre-funded warrants as of the September 1, 2026 record date.

What is not verified: human efficacy, clinically meaningful muscle preservation, the robustness of the full IBIO-610 dataset once presented at EASD, the specific composition and IND timeline of the selected IBIO-800 candidate, an exact IBIO-600 multiple-ascending-dose completion month, a final meeting record-date ownership table or a defensible analyst consensus target.

The investment question is therefore clear. At a common-plus-pre-funded economic value around $194 million ($1.26, the close of September 2, 2026), investors are no longer paying only for a laboratory platform. They are paying for translation, now backed by a materially larger cash position than a year ago. The next evidence must come from humans in the multiple-ascending-dose portion, and the share-count convention must stay visible every time the valuation is discussed.